UNSPSC 51332526: Pipamperone hydrochloride

This classification denotes an anxiolytic with the molecular formula C21H30FN3O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IT085U64JB, chemically known as 1-(3-(p-fluorobenzoyl)propyl)-(1,4-bipiperidine)-4-carboxamide but more generally known as pipamperone hydrochloride, which bears US NIH Compound Identifier 4830. European Medicines Agency schedules Pipamperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03835MIG.

Most nations, for tariff and trade purposes, schedule pipamperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PIPAMPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1C(=O)CCCN2CCC(CC2)(C(=O)N)N3CCCCC3)F.CL.CL.

UNSPSC 51332526 Pipamperone hydrochloride is a Commodity code that identifies a single pharmaceutical product, but recent state and local procurement activity shows little direct solicitation for this specific drug. The three most recent opportunities posted under or near this code span different pharmaceutical procurement models—a county naloxone and drug deactivation systems purchase, a state health agency's exploratory request for information on direct-to-manufacturer prescription programs, and a multistate cooperative purchasing alliance's generic pharmaceutical and OTC product contract—none of which explicitly reference pipamperone hydrochloride in their documented scope. The mismatch between the code's specificity and the actual buying patterns suggests that state and local governments may be procuring this compound under broader pharmaceutical codes, through group purchasing organizations, or as a component within larger mental-health or institutional-pharmacy contracts rather than as a standalone line item.

Issuing bodies active in the pharmaceutical space include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing groups (Minnesota Multistate Cooperative Purchasing Alliance, which serves multiple states including Oregon). Recent opportunities show procurement concentrated in Florida, Texas, and the Upper Midwest, with the Minnesota cooperative serving a multi-state footprint. The Seminole County naloxone IFB (IFB60459723LAS, due July 26, 2023) represents the most concrete recent activity, though it targets opioid-reversal and drug deactivation rather than pipamperone. The Texas RFI (HHS0017013, April 2026) and Minnesota MMCAP RFP for generic pharmaceuticals (S1070000015802, due March 26, 2026) indicate state-level interest in pharmaceutical supply-chain efficiency and direct manufacturer relationships, but neither documentation names pipamperone specifically. The code shows limited recent relevant activity; firms pursuing pharmaceutical contracts should monitor broader generic-drug and institutional-pharmacy codes where state and local demand appears more concentrated.